WO2008106202A1 - Modulateurs de théramutéine - Google Patents

Modulateurs de théramutéine Download PDF

Info

Publication number
WO2008106202A1
WO2008106202A1 PCT/US2008/002656 US2008002656W WO2008106202A1 WO 2008106202 A1 WO2008106202 A1 WO 2008106202A1 US 2008002656 W US2008002656 W US 2008002656W WO 2008106202 A1 WO2008106202 A1 WO 2008106202A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
alkyl
aryl
aralkyl
membered
Prior art date
Application number
PCT/US2008/002656
Other languages
English (en)
Inventor
Gerard M. Housey
Original Assignee
Housey Gerard M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Housey Gerard M filed Critical Housey Gerard M
Publication of WO2008106202A1 publication Critical patent/WO2008106202A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants.
  • inhibitors and activators of endogenous protein variants encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
  • P-gp P-glycoprotein
  • P-gp protein known as P-glycoprotein
  • the protein is capable of pumping toxic chemical agents, including many classical anti -cancer drugs, out of the cell. Consequently, upregulation of P-glycoprotein usually results in resistance to multiple drugs. Upregulation of P-glycoprotein in tumor cells may represent a defense mechanism which has evolved in mammalian cells to prevent damage from toxic chemical agents.
  • Other related drug resistance proteins have now been identified with similar functions to P-gp, including multidrug-resistance-associated protein family members such as MRPl and ABCG2. In any event, with the advent of the development of compounds that are specific for a given target protein, and less toxic, the importance of P-glycoprotein and related ATP-binding cassette (ABC) transporter proteins in clinically significant drug resistance has lessened.
  • ABSC ATP-binding cassette
  • Another possible molecular mechanism of acquired drug resistance is that alternative signal pathways are responsible for continued survival and metabolism of cells, even though the original drug is still effective against its target. Furthermore, alterations in intracellular metabolism of the drug can lead to loss of therapeutic efficacy as well. In addition, changes in gene expression as well as gene amplification events can occur, resulting in increased or decreased expression of a given target protein and frequently requiring increasing dosages of the drug to maintain the same effects. (Adcock and Lane, 2003)
  • Mutation induced drug resistance is a frequently occurring event in the infectious disease area.
  • several drugs have been developed that inhibit either the viral reverse transcriptase or the viral protease encoded in the human immunodeficiency (HIV) viral genome.
  • HIV human immunodeficiency
  • New evidence shows that drug resistance can also arise from a mutational event involving the gene encoding the drug target (Gorre et al., Science, 2001; PCT/US02/18729).
  • a specific therapeutic substance such as a given cancer drug that targets a specific protein-of-interest (POI, or "target” protein)
  • POI protein-of-interest
  • Chronic myelogenous leukemia is characterized by excess proliferation of myeloid progenitors that retain the capacity for differentiation during the stable or chronic phase of the disease.
  • Multiple lines of evidence have established deregulation of the AbI tyrosine kinase as the causative oncogene in certain forms of CML.
  • the deregulation is commonly associated with a chromosomal translocation known as the Philadelphia chromosome (Ph), which results in expression of a fusion protein comprised of the BCR gene product fused to the Abelson tyrosine kinase, thus forming p210 Bcr Abl which has tyrosine kinase activity.
  • Pr Philadelphia chromosome
  • pl90 Bcr A related fusion protein, termed pl90 Bcr" ⁇ bl , that arises from a different breakpoint in the BCR gene, has been shown to occur in patients with Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (MeIo, 1994; Ravandi et al., 1999). Transformation appears to result from activation of multiple signal pathways including those involving RAS, MYC, and JUN.
  • Imatinib mesylate (“STI-571" or "Gleevec®” is a 2-phenylamino pyrimidine that targets the ATP binding site of the kinase domain of AbI (Druker et al, NEJM 2001, p. 1038).
  • PDGF platelet-derived growth factor
  • Kit tyrosine kinase the latter of which is involved in the development of gastrointestinal stromal tumors (see below).
  • the mutations that emerged conferred upon the mutant protein a relative resistance to the effects of the protein kinase inhibitor drug, while maintaining a certain degree of the original substrate specificity of the mutant protein kinase.
  • a compound which inhibited the Abelson protein kinase such as STI-571, would have resulted from one or more of the other mechanisms of drug resistance listed above, or by some other as yet unknown mechanism, but that in any event said resistance would involve a target (protein or otherwise) which was distinct from the drug's target POI.
  • mutated proteins are beginning to be recognized and understood to be important targets in recurring cancers, and will become important in other diseases as well.
  • therapeutic agents that are active against such drug resistant variant forms of cellular proteins that may arise before, during or following normally effective drug therapies.
  • a key purpose of this invention is to provide compounds that may serve as potential therapeutic agents useful in overcoming mutation-induced drug resistance in endogenously occurring proteins.
  • This invention relates to agents that are inhibitors or activators of variant forms of proteins.
  • the invention also relates to agents that are inhibitors or activators of certain variant forms of endogenous proteins.
  • inhibitors and activators of endogenous protein variants encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
  • mutant proteins Such protein variants (mutant proteins) are herein termed “theramuteins,” and may occur either spontaneously in an organism (and be pre-existing mutations in some cases), or said mutants may arise as a result of selective pressure which results when the organism is treated with a given chemical agent capable of inhibiting the non-mutated form of said theramutein (herein termed a "prototheramutein”). It will be understood that in some cases a prototheramutein may be a "wild type" form of a POI (e.g., a protein that gives rise to a disease due to disregulation).
  • POI wild type form of a POI
  • the prototheramutein will be a disease causing variant of a "wild type” protein, having already mutated and thereby contributing to the development of the diseased state as a result of said prior mutation.
  • One example of the latter type of prototheramutein is the P210 BCR"ABL oncoprotein, and a mutant form of this protein harboring a threonine (T) to isoleucine (I) mutation at position 315 is termed p2io BCR ABL T3151 and is one example of a theramutein.
  • the designation "P210 BCR - ABL " is synonymous with the term “p210 Bcr Abl ", the "wild-type Bcr- AbI protein", and the like.
  • Theramuteins are a rare class of endogenous proteins that harbor mutations that render said proteins resistant to drugs that are known to inhibit or activate in a therapeutically effective manner their non-mutated counterparts.
  • the endogenous genes encoding a few such proteins are presently known to exhibit such mutations under certain circumstances.
  • this invention is directed toward compositions that inhibit certain drug-resistant mutants (theramuteins) of the Abelson tyrosine kinase protein, originally termed P210-Bcr-Abl in the literature, that is involved in the development of chronic myelogenous leukemia.
  • the present invention is particularly directed toward the identification of specific inhibitors or specific activators of proteins.
  • Use of the term “specific” in the context of the terms “inhibitor” or “activator” means that said inhibitor or activator binds to the protein and inhibits or activates the cellular functioning of the protein without also binding to and activating or inhibiting a wide variety of other proteins or nonprotein targets in the cell.
  • the skilled investigator is well aware that there is a certain degree of variability in the medical literature with respect to the concept of a specific inhibitor or a specific activator, and of the related concept of target protein "specificity" when discussing the actions of inhibitors or activators of a protein.
  • a substance is a specific inhibitor or a specific activator of a given protein if said substance is capable of inhibiting or activating said protein at a given concentration such that a corresponding phenoresponse is modulated in the appropriate manner, without having an appreciable effect at the same given concentration upon the phenoresponse (if any) of a corresponding control cell that essentially does not express the protein.
  • a substance may be a modulator of two closely related proteins such as a prototheramutein and one of its corresponding theramuteins.
  • a substance in addition to being a modulator of the prototheramutein and theramutein, a substance may also modulate the activities of proteins that have similar functions.
  • imatinib mesylate in addition to inhibiting the p210 Bcr Abl tyrosine kinase, imatinib mesylate is also capable of inhibiting the c-kit oncogene product (also a tyrosine kinase) which is overexpressed in certain gastrointestinal stromal tumors, as well as the PDGF ⁇ receptor (also a tyrosine kinase), which is expressed in certain chronic myelomonocytic leukemias (CMML).
  • CMML chronic myelomonocytic leukemias
  • the invention also provides a general method that can be used to identify substances that will activate or inhibit a theramutein, to the same extent, and preferably to an even greater extent than a known drug substance is capable of inhibiting the corresponding "wild type” form of that protein. (The skilled artisan is well aware, however, that said "wild type” forms of such proteins may have already mutated in the course of giving rise to the corresponding disease in which said protein participates.)
  • the present invention provides inhibitors of the p210 BCR - ABL - ⁇ 3i s i meramutein having the formula I
  • ring A is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring;
  • X 1 is selected from N, N-R 0 or C-R 1 ;
  • X 2 is selected from N, N-R 0 or C-R 1 ; each R 1 is independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 11 , -(CH 2 ) p C(O)(CH 2 ) 9 R n , -(CH 2 ) ⁇ C(O)N(R 12 )(R 13 ), -(CH 2 ) P C(O)O(CH 2 ) 9 R 11 ,-(CH 2 ) P N(R 11 )(CH 2 ) 9 C(O)R 11 , -(CH 2 ) P N(R 12 )(R 13 ), -(CH 2 ) P N(R 11 XCH 2 ),-* 11 , -N(R ⁇ )SO 2 R u , -OC(O)N(R 12 )(R 13 ), -SO 2
  • Ring B and Ring B' are a 5-, or 6- membered ring
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 3 is selected from N, C and CH;
  • R 4 is selected from N, C or CH;
  • b is O, I, or 2; dashed lines represent optional double bonds;
  • Ring C is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring; each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B or Ring B' and to Ring C; R 7 is -Q-R 9 ;
  • Q is selected from a chemical bond or a group having the formula -O-, -(CH 2 ),-, -(CH 2 ) ( C(O)(CH 2 ) y -, -(CH 2 ) r N(R 71 )-(CH 2 ) / -, -(CH 2 ),C(O)-N(R 71 )-(CH 2 ) / -, -(CH 2 XC(O)O(CH 2 V, -(CH 2 ),N(R 71 )C(O)-(CH 2 V, -(CH 2 ),OC(O)N(R 71 MCH 2 ),-, and -O-(CH 2 ),-C(O)N(R 71 )-(CH 2 V;
  • R 71 is selected from H, alkyl, aryl, and a heterocyclic ring
  • R 9 is selected from an aryl and a heterocyclic ring
  • i is O to 4
  • j is 0 to 4
  • each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring
  • c is 0 to 3
  • d is O or 1.
  • the invention provides for a fundamentally new way of treating cancer and other diseases where treatment with an existing drug compound, by whatever mechanism, is followed by identifiable (clinically significant) theramutein-mediated drug resistance, by providing alternative drugs that can be administered as theramuteins arise and are identified as such (Wakai et al., 2004, reports an example wherein a theramutein may arise during the course of an on-going treatment regimen), or preemptively before the outgrowth of clinically significant populations of theramutein expressing cells.
  • the invention enables the tailoring of treatments for those subjects by providing alternative drug substances that will be effective against said theramutein.
  • the invention provides a method of determining whether a chemical agent is at least as effective a modulator of a theramutein in a cell as a known substance is a modulator of a corresponding prototheramutein.
  • One embodiment of the method involves contacting a control cell that expresses the prototheramutein and is capable of exhibiting a responsive phenotypic characteristic (linked to the functioning of the prototheramutein in the cell) with the known modulator of the prototheramutein, contacting a test cell that expresses the theramutein and is also capable of exhibiting the responsive phenotypic characteristic (linked to the functioning of the theramutein in the cell) with the chemical agent, and comparing the response of the treated test cell with the response of the treated control cell; to determine that the chemical agent is at least as effective a modulator of the theramutein as the known substance is a modulator of the pro to theramutein.
  • one type of control cell may not express the prototheramutein at all.
  • the control cell may express about the same amount of the prototheramutein as the test cell expresses of the theramutein.
  • the control cell may be capable of exhibiting the responsive phenotypic characteristic to about the same extent as the test cell under certain conditions.
  • the test cell may express a given protein, whereas the control cell expresses little or essentially none of the protein.
  • Proteins of the invention that are of particular interest are those involved in regulatory function, such as enzymes, protein kinases, tyrosine kinases, receptor tyrosine kinases, serine threonine protein kinases, dual specificity protein kinases, proteases, matrix metalloproteinases, phosphatases, cell cycle control proteins, docking proteins such as the IRS family members, cell-surface receptors, G-proteins, ion channels, DNA- and RNA- binding proteins, polymerases, and the like.
  • regulatory function such as enzymes, protein kinases, tyrosine kinases, receptor tyrosine kinases, serine threonine protein kinases, dual specificity protein kinases, proteases, matrix metalloproteinases, phosphatases, cell cycle control proteins, docking proteins such as the IRS family members, cell-surface receptors, G-proteins, ion channels, DNA- and RNA- binding proteins, polymer
  • Any responsive phenotypic characteristic that can be linked to the presence of the protein (including, e.g., a theramutein or prototheramutein) in the cell can be employed for use in the method, including, for example, growth or culture properties, the phosphorylation state (or other modification) of a substrate of the theramutein, and any type of transient characteristic of the cell, as will be defined and discussed in detail.
  • Figure 1 shows the effect on growth and viability of different concentrations of Compound 2 (C2) for non-transformed vector control Ba/F3 cells (which are IL-3 dependent) as well as Ba/F3 cells expressing the "wild type" p210 Bcr Abl (designated p210 Bcr" AbI wt ), and Ba/F3 cells expressing the p 2io Bcr"Abl"T3151 drug resistant mutant.
  • C2 Compound 2
  • STI-571 potently inhibits growth of the P210 cell line (grey bar) whereas it is unable to inhibit the growth of the T315I cell line (white bar) even at 10 ⁇ M concentration.
  • 500 nM C2 shows the largest specificity gap within this dose-response series. Compare STI-571 at 10 ⁇ M to C2 at 500 nM on the T315I cell line (white bars).
  • Figure 2 shows the effect on growth and viability of different concentrations of Compound 6 (C6) for non-transformed vector control Ba/F3 cells as well as Ba/F3 cells expressing the p2io Bcr Abl T3151 drug resistant mutant. All other details are as per Fig. 1.
  • Figure 3 shows various determinations of the specificity gap by comparing the effects of various compounds identified in the screen in terms of their effects on the prototheramutein- and theramutein-expressing cell lines.
  • Compound 3 (C3) shows the best example of the ability of the method to identify a compound that exerts an even greater effect on the theramutein than on its corresponding prototheramutein.
  • Panel E Panel A: control DMSO treatments; B: negative heterologous specificity gap; C: slightly positive heterologous specificity gap; D: large positive homologous specificity gap; E: positive heterologous specificity gap. See text for explanations.
  • halo or halogen as used herein includes fluorine, chlorine, bromine and iodine.
  • alkyl as used herein contemplates substituted and unsubstituted, straight and branched chain alkyl radicals having from 1 to 6 carbon atoms.
  • Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-b ⁇ ity ⁇ , and the like. Additionally, the alkyl group may be optionally substituted with one or more substituents selected from halo, CN, CO 2 R, C(O)R, C(O)NR 2 , NR 2 , cyclic-amino, NO 2 , and OR.
  • cycloalkyl as used herein contemplates substituted and unsubstituted cyclic alkyl radicals.
  • Preferred cycloalkyl groups are those with a single ring containing 3 to 7 carbon atoms and include cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • Other cycloalkyl groups may be selected from C 7 to Cio bicyclic systems or from C 9 to C] 4 tricyclic systems.
  • cycloalkyl group may be optionally substituted with one or more substituents selected from halo, CN, CO 2 R, C(O)R, C(O)NR 2 , NR 2 , cyclic- amino, NO 2 , and OR.
  • alkenyl as used herein contemplates substituted and unsubstituted, straight and branched chain alkene radicals. Preferred alkenyl groups are those containing two to six carbon atoms.
  • alkenyl group may be optionally substituted with one or more substituents selected from halo, CN, CO 2 R, C(O)R, C(O)NR 2 , NR 2 , cyclic- amino, NO 2 , and OR.
  • alkynyl as used herein contemplates substituted and unsubstituted, straight and branched chain alkyne radicals. Preferred alkynyl groups are those containing two to six carbon atoms. Additionally, the alkynyl group may be optionally substituted with one or more substituents selected from halo, CN, CO 2 R, C(O)R, C(O)NR 2 , NR 2 , cyclic- amino, NO 2 , and OR.
  • aralkyl as used herein contemplates an alkyl group which has as a substituent an aromatic group, which aromatic group may be substituted and unsubstituted.
  • the aralkyl group may be optionally substituted on the aryl with one or more substituents selected from halo, CN, CF 3 , NR 2 , cyclic-amino, NO 2 , OR, CF 3 , -(CH 2 XR, -(CH 2 XC(O)(CH 2 ) ⁇ R, -(CH 2 XC(O)N(R 1 XR"), -(CH 2 XC(O)O(CH 2 ⁇ R, -(CH 2 XN(R 1 XR"), -N(R)SO 2 R, -0(CH 2 XC(O)N(R 1 XR"), -SO 2 N(R')(R"), -(CH 2 XN(R)-(CH 2
  • heterocyclic group or "heterocyclic ring” as used herein contemplates aromatic and non-aromatic cyclic radicals having at least one heteroatom as a ring member.
  • Preferred heterocyclic groups are those containing 5 or 6 ring atoms which includes at least one hetero atom, and includes cyclic amines such as morpholino, piperidino, pyrrolidino, and the like, and cyclic ethers, such as tetrahydrofuran, tetrahydropyran, and the like.
  • Aromatic heterocyclic groups also termed "heteroaryl” groups contemplates single-ring hetero-aromatic groups that may include from one to three heteroatoms, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • heteroaryl also includes polycyclic hetero- aromatic systems having two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is a heteroaryl, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • polycyclic heteroaromatic systems include quinoline, isoquinoline, tetrahydroisoquinoline, quinoxaline, quinaxoline, benzimidazole, benzofuran, purine, imidazopyridine, benzotriazole, and the like.
  • heterocyclic groups may be optionally substituted with halo, CN, CF 3 , NR 2 , cyclic-amino, NO 2 , OR, CF 3 , -(CH 2 ⁇ C(O)(CH 2 yt, -(CH 2 XC(O)N(R 1 XR"), -(CH 2 ⁇ C(O)O(CH 2 ⁇ R, -(CH 2 ) ⁇ N(R 1 XR"), -N(R)SO 2 R, -0(CH 2 ) ⁇ C(O)N(R 1 XR"), -SO 2 N(R)(R"), -(CH 2 ) ⁇ N(R)-(CH 2 VR, -(CH 2 XN(R)-C(O)-(CH 2 VR, -(CH 2 ⁇ N(R)-C(O)-O-(CH 2 ⁇ -R, -(CH 2 ⁇ -C(O)-N(R)-(CHCH 2
  • cyclic-amino contemplates aromatic and non- aromatic cyclic radicals having at least one nitrogen as a ring member.
  • Preferred cyclic amino groups are those containing 5 or 6 ring atoms, which includes at least one nitrogen, and includes morpholino, piperidino, pyrrolidino, piperazino, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine and the like.
  • the cyclic-amino may be optionally substituted with halo, CN, CF 3 , NR 2 , NO 2 , OR, CF 3 , substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted alkenyl, substituted and unsubstituted alkynyl, substituted and unsubstituted aryl, and a substituted and unsubstituted heterocyclic ring, wherein the substituted alkyl, substituted cycloalkyl, substituted aralkyl, substituted alkenyl, substituted alkynyl, substituted aryl, and substituted heterocyclic ring may be substituted with one or more of halo, CN, CF 3 , CO 2 R, C(O)R, C(O)NR 2 , NR 2 , NO 2 , and OR.
  • aryl or "aromatic group” as used herein contemplates single-ring aromatic groups (for example, phenyl, pyridyl, pyrazole, etc.) and polycyclic ring systems (naphthyl, quinoline, etc.).
  • the polycyclic rings may have two or more rings in which two atoms are common to two adjoining rings (the rings are "fused") wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, aryl, heterocycles and/or heteroaryls.
  • the aryl groups may be optionally substituted with one or more substituents selected from halo, CN, CF 3 , NR 2 , cyclic-amino, NO 2 , OR, CF 3 , -(CH 2 ) ⁇ C(O)(CH 2 ) ⁇ R, -(CH 2 ⁇ C(O)N(R 1 XR"), -(CH 2 ) ⁇ C(O)O(CH 2 ) ⁇ R, -(CH 2 ) ⁇ N(R 1 XR"), -N(R)SO 2 R, -0(CH 2 ) ⁇ C(O)N(R 1 XR"), -SO 2 N(RO(R"), -(CH 2 ) ⁇ N(R)-(CH 2 VR, -(CH 2 ) x N(R)-C(O)-(CH 2 ) r R, -(CH 2 ) ⁇ N(R)-C(O)-O-(CH 2 ) r R,
  • heteroatom particularly as a ring heteroatom, refers to N, O, and S.
  • Each R is independently selected from H, substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted aryl and a substituted and unsubstituted heterocyclic ring, wherein the substituted alkyl, substituted cycloalkyl, substituted aralkyl, substituted aryl and substituted heterocyclic ring may be substituted with one or more halo, CN, CF 3 , OH, CO 2 H, NO 2 , C,.
  • R 1 and R" are independently selected from H, or substituted and unsubstituted alkyl, substituted and unsubstituted cycloalkyl, substituted and unsubstituted aralkyl, substituted and unsubstituted aryl and a substituted and unsubstituted heterocyclic ring, wherein the substituted alkyl, substituted cycloalkyl, substituted aralkyl, substituted aryl and substituted heterocyclic ring may be substituted with one or more halo, CN, CF 3 , OH, CO 2 H, NO 2 , Ci- 6 alkyl, -Q-(Ci - ⁇ alkyl), -NH 2 , or R' and R" may be taken together with the nitrogen to which they are attached form
  • the present invention provides inhibitors of the P 210 BCR - ABL - T3 I SI theramute j n having the formula I
  • ring A is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring
  • X 1 is selected from N, N-R 0 or C-R 1
  • X 2 is selected from N, N-R 0 or C-R 1
  • each R 1 is independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 11 , -(CH 2 ) p C(O)(CH 2 ) 9 R n , -(CH 2 ) P C(O)N(R 12 )(R 13 ), -(CH 2 ) P C(O)O(CH 2 ) (?
  • Ring B and Ring B' are a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 3' is selected from N, C and CH;
  • R 4 is selected from N, C or CH;
  • 6 is O, I, or 2; dashed lines represent optional double bonds;
  • Ring C is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring; each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B or Ring B' and to Ring C; R 7 is -Q-R 9 ;
  • Q is selected from a chemical bond or a group having the formula -O-, -(CH 2 ),-, -(CH 2 )AO)(CH 2 ),-, -(CH 2 ),-N(R 71 )-(CH 2 ) 7 -, -(CH 2 ),C(O)-N(R 71 )-(CH 2 ) r , -(CHz) 1 C(O)O(CH 2 ),-, -(CH 2 ),N(R 71 )C(O)-(CH 2 ) / -, -(CH 2 ),OC(O)N(R 71 )-(CH 2 ) r , and -0-(CH 2 X-C(O)N(R 71 MCH 2 V; R 71 is selected from H, alkyl, aryl, and a heterocyclic ring;
  • R 9 is selected from an aryl and a heterocyclic ring; i is O to 4; j is O to 4; each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring; c is O to 3; and d is O or 1.
  • Ring A is an aromatic ring.
  • X 1 or X 2 is N. In another preferred embodiment, both X 1 and X 2 are N.
  • Ring A is a pyridine ring or a pyrimidine ring. In still further preferred embodiments, Ring A is selected from the structures provided below:
  • Ring C is a 6-membered aryl group, including phenyl, pyridyl, and pyrimidyl. Pyridyl is particularly preferred.
  • Ring C is a 10-membered bicyclic aryl group, including naphthyl, quinoline, isoquinoline, quinazoline, and quinoxaline.
  • Ring B is selected from the following chemical groups:
  • Ring B' is selected from the following chemical groups:
  • the present invention provides inhibitors of the p2i ⁇ BCR ABL - T3151 theramutein having the formula II
  • Ring A is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring;
  • X 1 is selected from N, N-R 0 or C-R 1 ;
  • X 2 is selected from N, N-R 0 or C-R 1 ;
  • each R 1 is independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 11 , -(CH 2 ) p C(O)(CH 2 ) 9 R ⁇ , -(CH 2 ) P C(O)N(R 12 )(R 13 ), -(CH 2 ) p C(O)O(CH 2 ) (?
  • R 11 -(CH 2 VN(R 11 )(CH 2 ) I? C(O)R ⁇ , -(CH 2 ) p N(R 12 )(R 13 ), -(CH 2 ) ⁇ N(R 11 XCH 2 ),!* 11 , -N(R 1 ⁇ SO 2 R 11 , -OC(O)N(R 12 )(R 13 ), -SO 2 N(R 12 )(R 13 ), halo, aryl, and a heterocyclic ring, and additionally or alternatively, two R 1 groups on adjacent ring atoms form a 5- or 6-membered fused ring which contains from O to 3 heteroatoms; a is O to 4; each R 1 : is independently selected from H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, and a heterocyclic ring; each R 12 and R 13 are independently selected from H, alkyl, cyclo
  • Ring B is a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 4 is selected from N, C or CH;
  • b is O, I, or 2; dashed lines represent optional double bonds;
  • Ring C is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring; each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B and to Ring C; R 7 is -Q-R 9 ;
  • Q is selected from a chemical bond or a group having the formula -O-, -(CH 2 ),-, -(CH 2 ),C(O)(CH 2 ) r , -(CH 2 ) r N(R 71 )-(CH 2 ) 7 -, -(CH 2 ),C(O)-N(R 71 )-(CH 2 ) r , -(CH 2 )AO)O(CH 2 ),-, -(CH 2 ),N(R 71 )C(O)-(CH 2 ),-, -(CH 2 ),OC(O)N(R 71 )-(CH 2 ) y -, and -O-(CH 2 ),-C(O)N(R 71 )-(CH 2 ) y -;
  • R 71 is selected from H, alkyl, aryl, and a heterocyclic ring
  • R 9 is selected from an aryl and a heterocyclic ring
  • i is 0 to 4
  • j is 0 to 4
  • each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring
  • c is 0 to 3
  • d is 0 or 1.
  • the present invention provides inhibitors of the P210 BCR ABL"T315I theramutein having the formula III:
  • Ring B is a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 4 is selected from N, C or CH;
  • b is 0, 1, or 2; dashed lines represent optional double bonds;
  • Ring C is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring;
  • each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membere
  • Q is selected from a chemical bond or a group having the formula -O-, -(CH 2 ),-, -(CH 2 ⁇ C(O)(CH 2 ),-, -(CH 2 ) l -N(R 71 )-(CH 2 ),-, -(CH2) l C(O)-N(R 71 )-(CH2),-, -(CH 2 )AO)O(CH 2 ),-, -(CH 2 ),N(R 71 )C(O)-(CH 2 ),-, -(CH 2 ),OC(O)N(R 71 MCH 2 ),-, and -O-(CH 2 ),-C(O)N(R 71 )-(CH 2 ),-;
  • R 71 is selected from H, alkyl, aryl, and a heterocyclic ring;
  • R is selected from H and F; each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring; c is O to 3; and d is 0 or 1.
  • the present invention provides inhibitors of the P21O BCR ABL T3151 theramutein having the formula IV
  • Ring A is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring;
  • X 1 is selected from N, N-R 0 or C-R 1 ;
  • X 2 is selected from N, N-R 0 or C-R 1 ; each R 1 is independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 11 , -(CH 2 ) p C(O)(CH 2 ),R n , -(CH 2 ) P C(O)N(R 12 )(R 13 ), -(CH 2 ) P C(O)O(CH 2 ) (7 R 1 I ,-(CH 2 ) P N(R 11 )(CH 2 ) 9 C(O)R 11 , -(CH 2 ) P N(R 12 )(R 13 ), -(CH 2 ) ⁇ N(R 11 )(CH 2 ),R U , -N(R 1 ⁇ SO 2 R 1 1 , -OC(O)N(R 12 )(R 13 ), -SO 2 N
  • Ring B is a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 4 is selected from N, C or CH;
  • b is O, I, or 2;
  • ' dashed lines represent optional double bonds;
  • X 3 is selected from N, CH, and C-R 6 ;
  • each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B and to Ring C
  • Q is selected from a chemical bond or a group having the formula -O-, -(CH 2 ),-, -(CH 2 ), €(O)(CH 2 ) r , -(CH 2 )rN(R 71 )-(CH 2 ) r , -(CH 2 ),C(O)-N(R 71 )-(CH 2 ) / -, -(CH 2 )AO)O(CH 2 ),-, -(CH 2 ),N(R 71 )C(O)-(CH 2 ) y -, -(CH 2 ),OC(O)N(R 71 )-(CH 2 ) r , and -0-(CH 2 VC(O)N(R 71 MCH 2 ),-; R 71 is selected from H, alkyl, aryl, and a heterocyclic ring;
  • R is selected from an aryl and a heterocyclic ring; i is 0 to 4; j is 0 to 4; each R is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring; c is 0 to 3; and d is 0 or 1.
  • the present invention provides inhibitors of the P21O BCR ABL"T3151 theramutein having the formula V
  • Ring B is a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 4 is selected from N, C or CH;
  • ⁇ is O, 1, or 2; dashed lines represent optional double bonds;
  • X 3 is selected from N, CH, and C-R 6 ;
  • each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B and to Ring C; R
  • R 71 is selected from H, alkyl, aryl, and a heterocyclic ring;
  • R 8 is selected from H and F; each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring; c is 0 to 3; and d is O or 1.
  • the present invention provides inhibitors of the p2io BCR ABL T3151 theramutein having the formula VI:
  • Ring B is a 5-, or 6- membered ring;
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, NR 31 , O, S, CR 31 and CHR 31 ;
  • R 31 is selected from H, and alkyl;
  • R 4 is selected from N, C or CH;
  • ⁇ is O, I, or 2; dashed lines represent optional double bonds;
  • each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B and to Ring C;
  • R 90 is selected from N(R 92 ) 2 , CF 3 , and OH.
  • Q is selected to be -(CH 2 ),-N(R 71 )-(CH 2 ) y -.
  • ⁇ 1 is -NH-.
  • X 3 is N.
  • the present invention provides inhibitors of the P210 BCR ABL"T315l theramutein having the formula VII:
  • ring A is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring;
  • X 1 is selected from N, N-R 0 or C-R 1 ;
  • X 2 is selected from N, N-R 0 or C-R 1 ; the dotted lines represent optional double bonds; each R 1 is independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 11 , -(CH 2 ) P C(O)(CH 2 ) ⁇ R 11 , -(CH 2 ) P C(O)N(R 12 )(R 13 ), -(CH 2 )pC(O)O(CH 2 ) 9 R 11 ,-(CH 2 )pN(R 11 )(CH 2 ),C(O)R n , -(CH 2 )pN(R 12 )(R 13 ), -(CH 2 ) P N(R 11 XCH 2 X 7 R 11 , -N(R 1 ⁇ SO 2 R 11 , -OC(O)N(R 12 )(R 13
  • Ring B' is a 5-, or 6- membered ring:
  • R 2 is selected from N, C and CH;
  • R 3 is selected from N, C and CH;
  • R 4 is selected from N, C or CH;
  • ⁇ is O, I, or 2; dashed lines represent optional double bonds;
  • Ring C is a 5-, 6-, or 7- membered ring or a 7- to 12-membered fused bicyclic ring; each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fused to Ring B or Ring B 1 and to Ring C; R 7 is -Q-R 9 ;
  • Q is selected from a chemical bond or a group having the formula -0-, -(CH 2 ),-, -(CH 2 ),C(O)(CH 2 ) r , -(CH 2 ),-N(R 71 )-(CH 2 ) / -, -(CH 2 ) / €(O)-N(R 71 )-(CH 2 ) / -, -(CH 2 )AO)O(CH 2 ),-, -(CH 2 ),N(R 71 )C(OMCH 2 ),-, -(CH 2 ),OC(0)N(R 71 MCH 2 ),-, and -O-(CH 2 )rC(O)N(R 71 )-(CH 2 ) y -;
  • R 71 is selected from H, alkyl, aryl, and a heterocyclic ring
  • R 9 is selected from an aryl and a heterocyclic ring
  • / is 0 to 4
  • j is 0 to 4
  • each R 0 is independently selected from H, alkyl, cycloalkyl, aralkyl, aryl and a heterocyclic ring
  • c is 0 to 3
  • d is 0 or 1.
  • the present invention provides inhibitors of the P210 BCR ABL"T315I theramutein having the formula VIII:
  • Ring B' is a 5-, or 6- membered ring:
  • R 2 is selected from N, C and CH;
  • R 3' is selected from N, C and CH;
  • R 4 is selected from N, C or CH;
  • 6 is O, 1, or 2; dashed lines represent optional double bonds;
  • each R 6 is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, CN, CF 3 , NO 2 , OR 0 , NH 2 , halo, aryl, and a heterocyclic ring; additionally or alternatively an R 6 and an R 5 may be taken together to form a 5-, to 7- membered ring that is fuse
  • R is selected from H and F.
  • Exemplary compounds of the formula I- VIII include the following structures:
  • each expression e.g. alkyl, a, b, R, R', R 1 , etc., when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
  • both the cis- and trans- isomers are intended to be encompassed by the formulae depicted herein.
  • chemical structures may be depicted herein in either cis or trans configuration, both configurations are meant to be encompassed by the each of the formulae.
  • compounds of the invention may exist in several tautomeric forms. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds.
  • the compounds of the invention may generally be prepared from commercially available starting materials and known chemical techniques. Embodiments of the invention may be synthesized as follows. One of skill in the art of medicinal or synthetic chemistry would be readily familiar with the procedures and techniques necessary to accomplish the synthetic approaches given below.
  • ketone (c).
  • M refers to one of the electropositive elements including for example Li, Mg, and Zn. It will be understood be the skilled practitioner that for bivalent metals such as Mg or Zn, that an additional chemical moiety such as a halogen will be bound to the metal.
  • Suitable protective groups may include silyl ethers, acetals, esters and other groups well known to persons skilled in the art. Removal of the protective group and conversion to a suitable leaving group to give intermediate (d) may be carried out under conditions compatible with each individual Ring C.
  • Cyclization with hydrazine will give the hydrazone (e), which may be coupled with Ring A under either basic or organometallic conditions to give the product (f).
  • the coupling may be carried out in microwave reactor (condition a).
  • the coupling may be performed using an organometallic catalyst such as a palladium catalyst with a strong, non- nucleophilic base and heat.
  • Conditions for the coupling may be adapted from the processes disclosed in the art, for example, "Efficient nucleophilic substitution reactions of pyrimidyl and pyrazyl halides with nucleophiles under focused microwave irradiation" Y-J.
  • Ring B is a pyrazole or a derivative thereof may be prepared according to the following general Scheme 2.
  • Reaction conditions may be adapted from the processes disclosed in the art, for example,
  • Ring B is an imidazole, or a derivative thereof, may be prepared from the appropriately protected tributyl tin imidazole according to general Scheme 3.
  • PG is an appropriate protecting group.
  • Organometallic coupling with a halogenated Ring A or C will produce the monosubstitued imidazoles.
  • the reaction may be carried out using a palladium catalyst.
  • the disubstituted imidazole may be produced by reaction with halogenated Ring A or C using conditions described above.
  • Reaction conditions may be adapted from the processes disclosed in the art, for example, M. Hervet; I. Thery; A. Gueiffier; C. Enguehard-gueiffier, HeIv. Chim.
  • An appropriate halogenated Ring A or C is reacted with a 2 or 5-tributyltin thiazole.
  • the monosubstituted thiazole ring may be metallated using n-butyl lithium or similar strong base, with or without transmetallation, or by other means well known to those skilled in the art.
  • the metallated thiazole may be coupled with the appropriately halogenated Ring A or C derivative under organometallic conditions. Such conditions include heat and a palladium catalyst. Reaction conditions may be adapted from the processes disclosed in the art, for example, "Synthesis of the heterocyclic core of the GE2270 antibiotics and structure elucidation of a major degradation product.” G. Heckmann; T. Bach, Angew.
  • An appropriate Ring A or C carboxylic acid is prepared by reaction of a metallated Ring A or Ring C compound with carbon dioxide.
  • the metalation may be carried out using n-butyl lithium or equivalent thereof.
  • the carboxylic acid may be converted to the acid chloride using conventional reactions, including thionyl chloride or equivalent thereof. Conversion of the acid chloride to the keto-isocyanate and condensation with an Ring A or C hydrazone derivative will produce the desired triazolone. Reaction conditions may be adapted from the processes disclosed in the art, for example, "Heterocyclic Tautomerism. IV. The Solution and Crystal Structures of l-Aryl-3-phenyl-l,2,4-triazol-5-ones," A. D. Rae; C. G. Ramsay; P. J. Steel, Australian J. Chem. 1988, 41, 419-428.
  • Cycloaddition of an appropriate Ring A or Ring C alkyne with azide results in the respective triazole.
  • the alkyne may be prepared using a Sonagashira or other organometallic coupling reaction.
  • the other carbon atom of the alkyne may be protected with a silyl protective group, which is removed with fluoride prior to cycloaddition.
  • the monosubstituted triazole may be reacted with an appropriately halogenated Ring A or Ring C compound under conditions previously described to produce the desired triazole-bridged product.
  • Reaction conditions may be adapted from the processes disclosed in the art, for example, "Table annelated chiral NADH models with a rigidified amide part in the quinoline series: synthesis, reactivity and grafting on a Merrifield resin," C. Vitry, J.-L. Vasse; G. Tos; V. Levacher; G. Queguiner; J. Bourguignon, Tetrahedron 2001, 57, 3087-3098; "Copper-Catalyzed Synthesis of N-Unxubstituted 1 ,2,3-Triazoles from Nonactivated Terminal Alkynes," T. Jin; S. Kamijo; Y. Yamamoto, Eur. J. Chem.
  • protecting group means temporary modifications of a potentially reactive functional group which protect it from undesired chemical transformations.
  • protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and' ketals of aldehydes and ketones, respectively.
  • the field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991).
  • One embodiment of this invention is directed to any endogenously occurring mammalian target protein selected by the skilled investigator to be of interest for the identification and/or optimization of a compound as an inhibitor or activator of said protein.
  • selected proteins will already be known to be involved in the etiology or pathogenesis of a human disease.
  • the invention is also directed toward mutant forms of such mammalian proteins.
  • a "mutein” is a protein having an amino acid sequence that is altered as a result of a mutation that has occurred in its corresponding gene (Wei gel et al, 1989). Such mutations may result in changes in one or more of the characteristics of the encoded protein.
  • an enzyme variant that has modified catalytic activity resulting from a change in one or more amino acids is a mutein.
  • This invention is concerned with proteins harboring an alteration of at least one amino acid residue (the terms "amino acid sequence change” or “amino acid sequence alteration” include changes, deletions, or additions, of at least one amino acid residue, or any combination of deletions, additions, changes) such that the resulting mutein has become (as a result of the mutation) resistant to a known therapeutic agent relative to the sensitivity of the non-mutated version of said protein to the therapeutic agent.
  • This specialized class of muteins is hereinafter referred to as a theramutein, and the corresponding protein lacking the mutation is referred to herein as aprototheramutein.
  • prototheramutein refers to an endogenously occurring protein in a cell that is susceptible to mutation that confers relative insensitivity (i.e. resistance) to a therapeutic compound which otherwise inhibits or activates the protein.
  • theramutein refers to an endogenously occurring protein or portion of a protein in a cell that contains at least one amino acid sequence alteration relative to an endogenous form of the protein, wherein the amino acid sequence change is or was identified or becomes identifiable, and is or has been shown to be clinically significant for the development or progression of a given disease, following exposure of at least one human being to a substance that is known to inhibit or activate the prototheramutein.
  • a substance need not be limited to a chemical agent for the purposes of first defining the existence of a theramutein.
  • a theramutein is a protein which harbors a mutation in its corresponding endogenous gene, wherein said mutation is associated with the development of clinical resistance in a patient to a drug that is normally able to activate or inhibit the non-mutated protein.
  • the term "corresponding prototheramutein” refers to the prototheramutein which, through mutation, gives rise to said theramutein.
  • the “corresponding theramutein” refers to the theramutein which has arisen by mutation from said prototheramutein.
  • the definition of a theramutein excludes proteins encoded by disease-causing infectious agents such as viruses and bacteria.
  • endogenous gene refers to a gene that has been present in the chromosomes of the organism at least in its unmutated form, since inception.
  • cell refers to a living eukaryotic cell whether in an organism or maintained under appropriate laboratory tissue or organ culture conditions outside of an organism.
  • the target protein may be any endogenously encoded mammalian protein.
  • the POI is a theramutein, which is a protein that is altered for the first time with respect to a commonly occurring "wild type" form of the protein (i.e., a wild type protein is the prototheramutein from which the theramutein arises).
  • a theramutein is a variant of a protein that is, itself, already a mutein (i.e., a mutein is the prototheramutein from which the theramutein arises).
  • a theramutein may be further mutated as compared to a previously existing theramutein.
  • the first theramutein such as the T315I mutant of p210 BCR-ABL (see below)
  • the first theramutein such as the T315I mutant of p210 BCR-ABL (see below)
  • T315I mutant such as the T315I mutant of p210 BCR-ABL (see below)
  • subsequent mutations of the (already mutated) T315I variant may be termed a secondary theramutein, tertiary theramutein, etc.
  • a mutein of the invention is a variant of Bcr-Abl tyrosine kinase that escapes inhibition by an inhibitor of the "wild type" Bcr-Abl.
  • Such a Bcr-Abl mutein is altered with respect to a more common or "wild type” form of Bcr-Abl (which is also a mutein as well) in
  • a protein of interest is an endogenously encoded mammalian protein.
  • a mutein of primary interest is a theramutein that may have the same, increased, or decreased specific activity relative to its prototheramutein, and that it is not inhibited or is poorly inhibited by an agent that is used to inhibit the prototheramutein.
  • another theramutein of primary interest is one that has the same, increased or decreased specific activity (relative to its prototheramutein) and that is not activated or is poorly activated by an agent that is used to activate the prototheramutein.
  • Other variations are obvious to the skilled artisan.
  • theramuteins can include naturally occurring or commonly observed variants of a protein, for example, variants that are expressed from different alleles of a particular gene. In some cases such variants may be unremarkable with respect to their normal cellular function, with functional differences becoming apparent only in the presence of agents that differentially inhibit or activate the cellular function of the variants.
  • naturally occurring variants of a particular enzyme may have activity profiles that are not substantially different, but a therapeutic agent that modulates one may be ineffective in modulating the other.
  • one aspect of the invention is the identification of an agent that is active against a selected POI whose cellular function contributes to a given disease state such that activators or inhibitors of said POI would be expected to be therapeutically effective during the course of treatment for the disease.
  • No limitation of any kind or nature is intended on the type of disease that may be treated, nor on the type of protein that may be targeted for modulation according to the teachings herein, provided that all other limitations stated herein are met, including the fact that any such protein that is selected for targeting must be an endogenous protein.
  • the skilled investigator may use non-endogenously occurring nucleic acids such as cDNAs in order to practice the method taught herein provided that the amino acid sequence corresponds to an endogenously occurring POI.
  • one aspect of the invention is the identification of an agent that is active against a protein or theramutein that arises or becomes dominant (by any mechanism) prior to or during the course of a treatment for a given disease
  • another aspect is the identification of an agent that is active against a mutein that is common within a population of unafflicted individuals, but wherein said mutein is less susceptible to modulation by an approved drug, and where the variation in the activity profile of the mutein becomes important (and is therefore first identified as being a theramutein) in a disease state such as where it is overexpressed or participates in a signaling process which has otherwise become abnormally regulated.
  • a neoplastic disease may be caused by abnormal regulation of a cellular component other than the theramutein or its prototheramutein, and still be treatable with an inhibitor of the prototheramutein, whereas the same treatment would be less effective or ineffective where the theramutein was present.
  • This can be an issue where it is observed that the response of a particular tumor type to an anticancer agent varies among individuals that express different variants of an enzyme against which the anticancer agent is directed (Lynch et al., 2004).
  • the variants would not have arisen or become predominant during the course of treatment of the disease, but are preexisting in the healthy population and are detected only by their altered responsiveness to a particular course of established therapeutic treatment.
  • agonist and “activator” of a protein are used interchangeably.
  • An activator is limited to a substance that binds to and activates the functioning of a given protein.
  • an “activator”, an “agonist”, and an “activator of a protein” are identical in meaning. The activation by an activator may be partial or complete.
  • the terms “antagonist” and “inhibitor” of a protein are used interchangeably.
  • An inhibitor is limited to a substance that binds to and inhibits the functioning of a given protein.
  • a substance "inhibit(s)" a protein means the substance binds to the protein and reduce(s) the protein's activity in the cell without materially reducing the amount of the protein in the cell.
  • a substance "activate(s)" a protein such as a prototheramutein or theramutein, is to state that the substance increases the defined function of the protein in the cell without substantially altering the level of the protein in the cell.
  • an "inhibitor”, an “antagonist” and an “inhibitor of a protein” are also synonymous.
  • the inhibition by an inhibitor may be partial or complete.
  • a modulator is an activator or an inhibitor.
  • an “activator OfPKCp 1” should be construed to mean a substance that binds to and activates PKC ⁇
  • an “inhibitor of p210 Bcr Abl” is a substance that binds to and inhibits the functioning of p210 Bcr”Abl .
  • To state that a substance "inhibits a protein” requires that the substance bind to the protein in order to exert its inhibitory effect.
  • to state that a substance "activates protein X” is to state that the substance binds to and activates protein X.
  • binding has their ordinary meanings in the field of biochemistry in terms of describing the interaction between two substances (e.g., enzyme-substrate, protein-DNA, receptor-ligand, etc.).
  • the term “binds to” is synonymous with “interacts with” in the context of discussing the relationship between a substance and its corresponding target protein.
  • the specificity gap refers to the difference between the ability of a given substance, under comparable conditions to inhibit the theramutein in a cell- based assay system of the invention as compared to either: a) the ability of the same substance under comparable conditions to inhibit the prototheramutein; or b) the ability of a second substance (usually a known inhibitor of the prototheramutein) to inhibit the theramutein under comparable conditions; or c) the ability of the second substance to inhibit the prototheramutein under comparable conditions.
  • heterologous specificity gap determinations (although (a) uses the same substance in both instances), whereas (b) is an example of a homologous specificity gap determination.
  • substances that are more effective against a theramutein have a "positive specificity gap.”
  • a "zero, null or no” specificity gap indicates that there is no significant measurable difference between the effect of a substance on the theramutein as compared to its effect on the prototheramutein (however such compounds may be quite useful in their ability to inhibit or activate both a theramutein and its corresponding prototheramutein), and a "negative specificity gap" indicates a substance that at a given concentration is less effective against the given theramutein than against a form of the corresponding prototheramutein or other comparative form of the theramutein (such as one that may harbor a different mutation).
  • the latter category is generally of lesser interest than the former categories of compounds, except in the case where the compound is so potent that its relatively lesser effect on the theramutein is of no real concern from the perspective of therapeutic efficacy.
  • the skilled investigator can easily recognize a variety of approaches to quantifying the specificity gap assessment in a manner tailored to his or her needs. Such an analysis may assist the skilled investigator in classifying various compounds into discrete categories that may be helpful in guiding further lead optimization or biological profiling studies on such compounds.
  • the invention also provides a means for identifying compounds that exhibit a desired specificity gap. Such compounds can be identified and their ability to inhibit or activate the theramutein determined using an in vitro cell-based assay system where the effect of a substance on the cellular functioning of the mutated endogenous form of the protein is compared to the effect of the same drug on the cellular functioning of a non-mutated endogenous form of the protein.
  • the system enables the discovery of compounds capable of binding to a theramutein and exerting a greater modulatory effect on the cellular functioning of said theramutein than on its corresponding prototheramutein. Further, the system enables the discovery of compounds capable of binding to a theramutein and exerting at least as great or greater modulatory effect on the cellular functioning of a theramutein than previously known compounds are able to exert on the corresponding prototheramutein.
  • a compound may be screened for and identified that 1) is at least as effective against the theramutein as the original drug is against the prototheramutein, and/or 2) is similarly effective against the prototheramutein as against the theramutein (i.e., displays a small or essentially zero specificity gap).
  • cells that overexpress a theramutein of interest are used to identify chemical agents that are inhibitors or activators of (i.e., that bind to and inhibit or that bind to and activate) at least the selected theramutein.
  • the chemical agents may also be inhibitors or activators of the prototheramutein or even other theramuteins of the same prototheramutein.
  • the terms "chemical agent” and “compound” are used interchangeably, and both terms refer exclusively to substances that have a molecular weight up to, but not including, 2000 atomic mass units (Daltons).
  • a theramutein is selected and used in a phenoresponse-based cellular assay system of the present invention designed to identify agents that are inhibitors or activators of the theramutein.
  • the degree of resistance of a theramutein to a given chemical agent is determined relative to its non- mutated counterpart (prototheramutein) using the drug that was first administered and known to inhibit or activate the prototheramutein and against which the theramutein "arose.”
  • the methods of determining the degree of such resistance for example by analysis Of IC 50 or AC 50 values, are well known and standard in the art and will not be reiterated herein.
  • the compound was still markedly less effective on the p210 Bcr"Abl theramuteins than it was against the wild-type p210 Bcr - Abi
  • the compoun( i was teste( i against p 2io Bcr Abl " T3151 mutant activity, it was unable to inhibit the activity to any appreciable extent (p. 1270, left hand column, second paragraph; see also Fig. 4.).
  • the disclosed compound was able to inhibit a theramutein that is partially resistant to STI-571, but had no activity against the T315I mutant of Bcr-Abl., which was already known at that time to be the theramutein that exhibited the most resistance to STI-571.
  • the Huron methodology failed to identify an effective inhibitor of the p210 Bcr Abl T3151 theramutein.
  • a test cell that displays a carefully selected phenotypic characteristic (as defined below) which is linked to the presence and functional activity of the particular protein-of-interest (POI) or theramutein-of-interest (TOI) in the cell under appropriate conditions.
  • POI protein-of-interest
  • TOI theramutein-of-interest
  • a phenotypic characteristic i.e. a non-genotypic characteristic of the cell
  • a phenotypic characteristic is a property which is observed (measured), selected and/or defined for subsequent use in an assay method as described herein.
  • phenotypic characteristic is responsive to the total activity of the protein in the cell, and is a result of the absolute amount of the protein and its specific activity. Often, the phenotypic characteristic is observable as a result of elevated levels of protein activity and is not apparent in cells that express low amounts of the protein, or if the protein is also a theramutein, then the phenotypic characteristic will often not be apparent in cells expressing low amounts of either the theramutein or its corresponding prototheramutein.
  • the phenotypic characteristic is modulated by modulating the specific activity of the protein with an inhibitor or activator of the theramutein, although this is not always the case since an inhibitor or activator of the TOI may not always be available at the time the skilled investigator undertakes such a project.
  • the skilled investigator may also use a substance capable of increasing or decreasing the expression of the gene encoding a given POI (such as a theragene in the case of a theramutein), which will in turn lead to increases or decreases of the level of the corresponding theramutein.
  • the selected phenotypic characteristic is linked to the activity of the theramutein in the test cell.
  • the selected phenotypic characteristic is usually also displayed by a cell that overexpresses the prototheramutein and in which the phenotypic characteristic is modulated by known inhibitors or activators of the prototheramutein.
  • a phenotypic characteristic is simply a characteristic of a cell other than a genotypic characteristic of the cell. Except for the specific requirements of a properly defined phenotypic characteristic as disclosed herein for the purposes of creating useful cellular assay systems according to the teachings of certain of the embodiments of the invention, no other limitation of the term phenotypic characteristic of any kind or nature is intended or appropriate in order to properly and effectively practice the invention. Indeed, the skilled artisan must be able to select any characteristic of the cell that maximizes the utility of establishing the proper cell-based assay for his or her needs.
  • the phenotypic characteristic can be quantitative or qualitative and be observable or measurable directly (e.g., observable with the naked eye or with a microscope), but most commonly the characteristic is measured indirectly using standard automated laboratory equipment and assay procedures which are known to those of skill in the art.
  • the term "observable” means that a characteristic may be measured or is otherwise detectable under appropriate conditions by any means whatsoever, including the use of any type of laboratory instrumentation available.
  • the term “detectable” is not the same as “detected.” A characteristic may be detectable to a skilled artisan without being detected at any given time, depending upon how the investigator chooses to design the assay system.
  • a POI such as a prototheramutein (or theramutein)
  • Phenotypic characteristics include but are not limited to growth characteristics, transformation state, differentiation state, substrate phosphorylation state, catalytic activity, ion flux across the cell membrane (calcium, sodium, chloride, potassium, hydrogen ions, etc.), pH changes, fluctuations of second messenger molecules or other intracellular chemical species such as cAMP, phosphoinositides, cyclic nucleotides, modulations of gene expression, and the like.
  • the characteristic of the cell may be observable or measurable continuously (e.g., growth rate of a cell), or after a period of time (e.g., terminal density of a cell culture), or transiently (e.g., modulation of a protein causes a transient change in phosphorylation of a substrate of the protein, or a transient flux in ion flow across the membrane, or elevations or reductions in intracellular cAMP levels).
  • a selected phenotypic characteristic may be detected only in the presence of a modulator of the protein. No limitations are intended with respect to a characteristic that may be selected for measurement.
  • a phenotypic characteristic can be focus formation that becomes observable when a cell that over expresses a selected protein is cultured in the presence of an activator of the protein, or it may be a transient increase or decrease in the level of an intracellular metabolite or ion, such as cAMP, calcium, sodium, chloride, potassium, lithium, phosphatidylinositol, cGMP, bicarbonate, etc.
  • the characteristic so measured may be determined on a sub-cellular fraction of the cell.
  • the initial treatment of the cell with a substance which thereby causes the substance to come into contact with the cell, must be performed on the intact cell, not a subcellular fraction.
  • the characteristic selected for measurement within the cell must not be an intrinsic physical or chemical property of the protein (or theramutein or prototheramutein) itself (such as the mere amount (mass) of the protein inside the cell), but rather must be a characteristic that results from the activity of the protein (or theramutein or prototheramutein) inside the cell, thus affecting a characteristic of the cell which is distinct from the theramutein itself, as discussed in detail above.
  • theramutein is a protein kinase that is capable of undergoing autophosphorylation
  • a process whereby the enzyme is capable of catalyzing the phosphorylation of itself by transferring a terminal phosphate group from ATP onto itself it would NOT be appropriate to select the phosphorylation state of the TOI as an appropriate phenotypic characteristic of the cell for measurement. This is because such a characteristic does not reflect the activity of the TOI on other cellular components.
  • autophosphorylation is not necessarily reflective of the activity of a protein kinase in a cell, since mutants of protein kinases are known that retain enzymatic activity sufficient to undergo autophosphorylation, yet have lost the capability to engage in signal transduction events within the cell.
  • the classic paper by White et al. (1988) is both educational and noteworthy in this respect.
  • responsive phenotypic characteristic means a characteristic of the cell which is responsive to inhibitors or activators of a given protein (including, e.g., a prototheramutein or theramutein).
  • known therapeutic agent is defined as any agent that has been administered to a human being for the treatment of a disease in a country of the world.
  • a useful phenotypic characteristic is disregulation of cell growth and proliferation. It is noted that the same or similar assay may be appropriate for use with many different proteins of interest. For example, disregulations of growth, proliferation, and/or differentiation are common phenotypic characteristics that may result from overexpression of a variety of different cellular proteins.
  • the characteristic becomes linked to the presence, amount, and specific activity of that selected protein under suitable conditions, and this linkage allows the skilled investigator to identify inhibitors or activators of a protein of interest (POI) as desired. Accordingly, the phenotypic characteristic is responsive to changes in the level and/or specific activity of the selected protein.
  • POI protein of interest
  • Such a responsive phenotypic characteristic when also demonstrated to be responsive to a known modulator of the POI is referred to herein as a "phenoresponse.”
  • a modulator of the prototheramutein In the special case of a theramutein which has no known modulator, a modulator of the prototheramutein must be utilized to establish a phenorespone to be used with the theramutein.
  • the conception and recognition of this highly useful property of a cell represents one of the substantial advances of this invention over the prior art, including Applicant's own prior original work in the general area of cell-based assays (U.S. Pat. Nos. 4,980,281; 5,266,464; 5,688,655; 5,877,007).
  • the identification and selection of the phenoresponse provides the skilled investigator with a cellular assay system that is extremely sensitive in terms of its ability to identify inhibitors or activators of the POI, and therefore identifies such chemical agents with a much higher degree of assurance than any other related assay method disclosed in the prior art.
  • the protein is stably expressed in a test cell.
  • Stable expression results in a level of the protein in the cell that remains relatively unchanged during the course of an assay.
  • stimulation or activation of a component of a signaling pathway may be followed by a refractory period during which signaling is inhibited due to down- regulation of the component.
  • down-regulation is usually sufficiently overcome by artificially overexpressing the protein.
  • the expression is sufficiently maintained that changes in a phenotypic characteristic that are observed during the course of an assay are due primarily to inhibition or activation of the protein, rather than a change in its level, even if down-modulation of the protein subsequently occurs.
  • transfection followed by transient expression of the protein may be employed provided that the selected phenotypic characteristic is measurable and the duration of the assay system is short relative to the progressive decline in the levels of the transiently expressed protein that is to be expected in such systems over time.
  • stably expressing cell lines are preferred (U.S. Patent No. 4,980,281).
  • the term "cellular specificity” means the ability of a compound, at a given concentration, to modulate a selected phenoresponse of the Test cell without affecting the Control Cell to the same extent, if at all.
  • the term "cellular specificity gap" (“CSG”) means a measurement of the ability of a selected compound to modulate the selected phenoresponse corresponding to a given target protein (not limited to a theramutein) in a test cell relative to the ability of said compound to modulate the same phenoresponse in a corresponding control cell.
  • the selected phenoresponse must have been previously defined using a known inhibitor or activator of the target protein.
  • Determination of the CSG provides the skilled investigator with a method of comparing the relative potential therapeutic value of different compounds within a group of compounds (two or more) by comparing their relative cross-reactivity with control cells irrespective of the potency against the target protein of any given compound within the group.
  • Compounds that exhibit the greatest "specificity" in their activity against test cells relative to control cells are generally the most desirable compounds, since a "wide" CSG will assist in selecting a compound that may reasonably be assumed to have minimal potential side effects in patients as compared to other compounds within the aforementioned group that have "narrow" CSGs.
  • the effects of the CSG measurement are seen most easily when comparing cell-based assay generated dose-response curves in their entirety, however the following hypothetical example is also instructive.
  • a standard approach in the art at the present time is to identify compounds that exhibit a high degree of potency with respect to inhibition of the target protein kinase's enzymatic activity in a cell-free assay system without showing significant inhibitory activity against a distinct but closely related protein kinase.
  • compound A is the most potent of the series of compounds (A, B, C, D) and also shows the largest difference between its IC 50 against the target protein relative to its effect on the non-target protein.
  • compound C is the least potent compound, it is the most specific in its ability to inhibit the Test cells while leaving the Control cells relatively unaffected over wide concentration range. This is reflected in its CSG of 40, and demonstrates that compound C, rather than compound A, is the compound that should be given the highest priority for further pre-clinical and clinical development efforts.
  • compound profiling is used to identify and/or minimize side effects associated with administration of a compound to a patient.
  • the cell-based lead optimization method allows early identification of potential side effects as compared to the cell-free approach.
  • imatinib shows a wide cellular specificity gap according to the methods of the invention described herein. This is consistent with imatinib' s significant advance in the area of anti-cancer drugs. However, it is not without side effects.
  • Recent evidence demonstrates that imatinib is associated with cardiac toxicity in a small percentage of patients (Kerkela et al., 2006). This group may increase over time as patients take imatinib for longer periods of time.
  • Imatinib tested at various concentrations on the wild type Ba/F3 cell line shows a slight but significant growth inhibitory effect at concentrations that are substantially below the apparent IC 50 for cellular toxicity (about 10 ⁇ M) on the control cell line that imatinib exhibits at markedly higher concentrations. Such results become even more evident when the comparison of the effects of other compounds on the Control cell line are compared to those of imatinib.
  • a preferred drug screening method for identification and optimization of compounds of the present invention involves the following:
  • a protein of interest such as a theramutein for which a novel inhibitor or activator is desired.
  • the POI is implicated or suspected to be implicated in establishment or maintenance of a disease state, perhaps due to inappropriate expression or a mutation-induced change in specific activity.
  • Identification of an appropriate theramutein may be performed using standard techniques (See, Gorre et al., Science, 2001; see also PCT/US 02/ 18729). Briefly, patients that have been given a course of a therapeutically effective treatment using an activator or inhibitor of a known or suspected prototheramutein and have subsequently shown clinical signs and symptoms consistent with disease relapse are identified, and cells or tissue samples derived from such patients are obtained.
  • the sequence of the prototheramutein is determined and compared to the previously determined nucleic acid sequence of the known prototheramutein gene or cDNA sequence. Mutations, if present, are identified and are correlated with functional resistance of the prototheramutein's function either in cell-based or, more commonly, cell-free assay systems, again using standard methodology. Once resistance-inducing mutations are confirmed, then said one or more confirmed mutants comprise a defined theramutein which may be used in the subsequent methods as described herein.
  • the theramutein of particular interest is p210 Bcr" ⁇ bl"T3151 , although the reactivities of the compounds with other theramuteins of p210 Bcr Abl are also of interest.
  • phenoresponse Such a phenotypic characteristic that is linked to expression of the POI and has been previously shown to be responsive to inhibitors or activators of the POI (or the prototheramutein-of-interest (pTOI)) is defined herein as a "phenoresponse.”
  • One embodiment of this invention is the definitive use of the phenoresponse for the purpose of identifying compounds that are likely to be inhibitors or activators of the TOI. This may be accomplished through the use of a high-throughput screen using a cell line overproducing a given TOI and for which an appropriate phenoresponse has been identified and characterized.
  • the theramutein is overexpressed, in some instances in a host cell that does not otherwise express the theramutein at all. This usually involves construction of an expression vector from which the theramutein can be introduced into a suitable host cell and overexpressed using standard vector systems and methodology. (Gorre et al., 2001 ; Housey et al., 1988). hi one embodiment, overexpression results in a level of the theramutein that is at least about 3 times the amount of the protein usually present in a cell. Alternatively, the amount is at least about 10 times the amount usually present in a cell, hi another embodiment, the amount is at least about 20 times or more preferably at least about 50 times the amount usually present in a cell.
  • control cell that expresses the POI to a lesser extent or not at all (e.g., an unmodified host cell or host cell harboring an expression vector that does not express the POI).
  • the control cell can also be a cell expressing the prototheramutein corresponding to the theramutein of interest.
  • the control cell usually displays substantially the same phenotypic characteristic as the test cell.
  • the phenotypic characteristic need not be quantitatively alike in both cells, however.
  • a mutation that leads to reactivation of the prototheramutein may also increase, decrease, or otherwise affect its specific activity with respect to one or more of its substrates in the cell. As a result, it may exhibit the selected phenotypic characteristic to a greater or lesser extent.
  • a properly defined phenoresponse may be quantitatively different between the prototheramutein- and the theramutein-expressing cell lines as a result of differences in the specific activity (if any) between the theramutein and its corresponding prototheramutein.
  • Theramutein-inducing mutations may increase or decrease the specific activity of said theramutein relative to the corresponding prototheramutein.
  • the selected phenoresponse is qualitatively the same in both cell types.
  • the skilled investigator may choose to normalize the activity of the theramutein-expressing cell line to that of the proto theramutein- expressing cell line, or vice versa.
  • Such normalization methods are standard in the art. See, for example, Bolstad et al. (2003).
  • the skilled investigator may also wish to use unmodified host cells or host cells harboring the expression vector only as control cells for certain experimental procedures.
  • the host cells are the cells into which an expression vector encoding the theramutein was introduced in order to generate the test cells.
  • This may be the case where the investigator is only interested in identifying a specific inhibitor or activator of the theramutein of interest, irrespective of whether or not said compound is also effective against the prototheramutein of interest (pTOI).
  • test and control cells are then maintained or propagated (although not necessarily at the same time) in growth media (or even in intact animals) under suitable conditions such that the phenoresponse may be expressed and assayed.
  • Control cells that are expressing the prototheramutein may be treated with a known modulator of the prototheramutein, or with a test substance, and test cells are treated with test compounds to determine whether they are active against the theramutein, as measured by the ability of said substances to modulate the phenoresponse in the expected manner.
  • control cells not expressing the prototheramutein may also be substituted, depending upon the particular phenoresponse that the skilled investigator has chosen for study. Substances may then be assayed on the test cells and, optionally, on the control cells at the same time, or at another time, and the results compared.
  • substances that are active with regard to the test cells can be rapidly identified by their ability to modulate the phenoresponse of the test cells in the same manner as, for example, the known modulator of the prototheramutein alters the phenoresponse of prototheramutein-expressing control cells.
  • active substances may be identified by their ability to modulate the activity of the theramutein in the test cells while having little or no effect on the unmodified (prototheramutein and/or theramutein non-expressing) control cells.
  • modulators that are more effective against the theramutein, or that are equally effective against both the prototheramutein and one or more corresponding specific theramuteins.
  • phenoresponses can be observed and/or measured and include, for example, detection of substrates of the prototheramutein, and detection of gene expression changes that are regulated by the activity of the theramutein.
  • any characteristic of the cell that the skilled investigator has previously correlated with the functional activity of the theramutein may be suitable for use with such methods.
  • the skilled investigator must first verify that said characteristic fulfills the criteria of being a phenoresponse according the teachings as given in detail herein.
  • the skilled investigator may also wish to normalize the phenoresponse with the theramutein expressing cells to that of the prototheramutein expressing cells.
  • Characteristics suitable for detection may be measured by a variety of methods very well known to those of skill in the art. Such methods include, but are not limited to, detection of fluorescence of suitably labeled proteins (FACS), immunohistochemistry (IHC) for detection of protein expression, competitive radioligand binding assays, solid matrix blotting techniques, such as Northern, Southern, and Western blots of cell extracts, reverse transcriptase polymerase chain reaction (RT-PCR), enzyme linked immunosorbent assays (ELISA), phosphorylation assays, gel retardation assays, membrane potential perturbations, and the like.
  • FACS fluorescence of suitably labeled proteins
  • IHC immunohistochemistry
  • solid matrix blotting techniques such as Northern, Southern, and Western blots of cell extracts, reverse transcriptase polymerase chain reaction (RT-PCR), enzyme linked immunosorbent assays (ELISA), phosphorylation assays, gel retardation assays, membrane potential perturbations, and the like.
  • the p210 Bcr"Abl prototheramutein and p 2l0 Bcr Abl - T3151 (or other) theramutein can each be expressed in Ba/F3 (murine) cells using standard methodology and the phenoresponses that are observed are growth characteristics (terminal cell density for a carefully defined cell culture, and growth in the absence of Interleukin-3 (IL-3). Unmodified host cells, or host cells containing the expression vector only or both, may optionally also be used. In still another embodiment, the test cells alone may be used with or without reference to a known inhibitor or activator.
  • Another useful assay is the determination of the state of phosphorylation of a direct substrate of p210 Bcr"Abl T3151 .
  • a direct substrate of p210 Bcr a direct substrate of p210 Bcr"Abl T3151 .
  • One such substrate is Crkl (Gorre et al., Science 293:876- 80 (2001)), an adapter protein which mediates the connection between Bcr-Abl and Ras.
  • the phosphorylation state of CRKL is representative of the signaling activity of p210 Bcr ⁇ Abl in a cell.
  • Another downstream substrate is p62DOK. Any such substrate would suffice for these purposes, provided of course that phosphorylation of said substrate has been shown to occur inside the cell, and is not simply an autophosphorylation event of the TOI or PTOI as discussed above.
  • Signal transduction cascade components may also be monitored, including src family kinases, STAT5, PD Kinase, raf kinase, RAS, MEK, ERKl and ERK2, JNKl, 2 and 3, MLKl, 2 and 3, MKK4, MKK7, AKT, mTOR, HSP90, and others.
  • src family kinases STAT5, PD Kinase, raf kinase, RAS, MEK, ERKl and ERK2, JNKl, 2 and 3, MLKl, 2 and 3, MKK4, MKK7, AKT, mTOR, HSP90, and others.
  • a therapeutically effective amount of one or more compounds that modulate the functional activity of a p210 Bcr ⁇ AbI theramutein is administered to a mammal in need thereof.
  • administering means delivering the compounds of the present invention to a mammal by any method that may achieve the result sought. They may be administered, for example, orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation.
  • mammal as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals.
  • “Therapeutically effective amount” means an amount of a compound that, when administered to a mammal, is effective in producing the desired therapeutic effect, such as inhibiting kinase activity, inhibiting cancer cell growth and division, etc.
  • the invention provides a method of treating disease in a mammal by administering to the mammal an effective amount of a modulator of a theramutein.
  • Suitable diseases to be treated according to the present invention include, but are not limited to, relapsing neoplastic or other proliferative disorders that have become resistant to previously administered drugs.
  • the method is also useful for overcoming variation among individuals with respect to susceptibility to drug treatment that results from allelic differences among therapy targets. For example, the role of p210 Bcr"Abl tyrosine kinase signaling in CML has been extensively demonstrated, as has the role of theramuteins of p210 Bcr"AbI in drug resistant recurrence of CML.
  • theramutein modulators are administered in combination with one or more other anti-neoplastic agents.
  • Any suitable anti-neoplastic agent can be used, such as a chemotherapeutic agent, radiation or combinations thereof.
  • the anti-neoplastic agent can be an alkylating agent or an anti-metabolite. Examples of alkylating agents include, but are not limited to, cisplatin, cyclophosphamide, melphalan, and dacarbazine.
  • anti-metabolites include, but not limited to, doxorubicin, daunorubicin, and paclitaxel, gemcitabine, and topoisomerase inhibitors irinotecan (CPT-11), aminocamptothecin, camptothecin, DX-8951 f, topotecan (topoisomerase I inhibitor), and etoposide (VP-16; topoisomerase II inhibitor) and teniposide (VM-26; topoisomerase II inhibitor).
  • the anti-neoplastic agent is radiation
  • the source of the radiation can be either external (external beam radiation therapy - EBRT) or internal (brachytherapy - BT) to the patient being treated.
  • the dose of anti-neoplastic agent administered depends on numerous factors, including, for example, the type of agent, the type and severity of the tumor being treated and the route of administration of the agent. It should be emphasized, however, that the present invention is not limited to any particular dose, route of administration, or combination of chemotherapeutic agents or other therapeutic regimens that are combined with the administration of protein modulators.
  • Anti-neoplastic agents which are presently known in the art or being evaluated can be grouped into a variety of classes including, for example, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti survival agents, biological response modifiers, anti-hormones, and anti-angiogenesis agents, all of which can be administered with inhibitors or activators of theramuteins.
  • a modulator of a theramutein can be administered with antibodies that neutralize other receptors involved in tumor growth. Further, a modulator of a theramutein can be administered with a compound that otherwise modulates a component of a signal transduction pathway, preferably a component of the signal transduction pathway in which the theramutein is active and which is common to one or more other signal transduction pathways, hi an embodiment of the invention, a theramutein modulator is used in combination with a receptor antagonist that binds specifically to the Epidermal Growth Factor Receptor (EGFR).
  • EGFR Epidermal Growth Factor Receptor
  • antigen-binding proteins that bind to the extracellular domain of EGFR and block binding of one or more of its ligands and/or neutralize ligand-induced activation of EGFR.
  • An EGFR antagonist can be an antibody that binds to EGFR or a ligand of EGFR and inhibits binding of EGFR to its ligand.
  • Ligands for EGFR include, for example, EGF, TGF- ⁇ , amphiregulin, heparin-binding EGF (HB-EGF) and betacellulin.
  • EGF and TGF- ⁇ are thought to be the main endogenous ligands that result in EGFR-mediated stimulation, although TGF- ⁇ has been shown to be more potent in promoting angiogenesis.
  • the EGFR antagonist can bind externally to the extracellular portion of EGFR, which can or can not inhibit binding of the ligand, or internally to the tyrosine kinase domain in the case of chemical agents.
  • EGFR antagonists that bind EGFR include, without limitation, biological agents such as antibodies (and functional equivalents thereof) specific for EGFR, and chemical agents (small molecules), such as synthetic kinase inhibitors that act directly on the cytoplasmic domain of EGFR.
  • growth factor receptors involved in tumorigenesis are the receptors for vascular endothelial growth factor (VEGFR-I and VEGFR-2), platelet-derived growth factor (PDGFR), nerve growth factor (NGFR), fibroblast growth factor (FGFR), and others.
  • VEGFR-I and VEGFR-2 vascular endothelial growth factor
  • PDGFR platelet-derived growth factor
  • NGFR nerve growth factor
  • FGFR fibroblast growth factor
  • the theramutein inhibitor is administered before, during, or after commencing therapy with another agent, as well as any combination thereof, i.e., before and during, before and after, during and after, or before, during and after commencing the anti-neoplastic agent therapy.
  • the theramutein inhibitor can be administered between 1 and 30 days, preferably 3 and 20 days, more preferably between 5 and 12 days before commencing radiation therapy.
  • chemotherapy is administered prior to, concurrently with or, more preferably, subsequent to antibody therapy.
  • any suitable method or route can be used to administer theramutein inhibitors of the invention, and optionally, to co-administer antineoplastic agents and/or antagonists of other receptors.
  • the anti-neoplastic agent regimens utilized according to the invention include any regimen believed to be optimally suitable for the treatment of the patient's neoplastic condition. Different malignancies can require use of specific anti-tumor antibodies and specific anti-neoplastic agents, which will be determined on a patient to patient basis.
  • Routes of administration include, for example, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration.
  • the dose of antagonist administered depends on numerous factors, including, for example, the type of antagonists, the type and severity of the tumor being treated and the route of administration of the antagonists. It should be emphasized, however, that the present invention is not limited to any particular method or route of administration.
  • Suitable carriers include, for example, one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. Carriers can further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffers, which enhance the shelf life or effectiveness of the theramutein modulator as the active ingredient.
  • the compositions can, as is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the mammal.
  • compositions of this invention can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions.
  • solid, semi-solid and liquid dosage forms such as tablets, pills, powders, liquid solutions, dispersions or suspensions, liposomes, suppositories, injectable and infusible solutions.
  • the preferred form depends on the intended mode of administration and therapeutic application.
  • compositions of the present invention are prepared in a manner well known in the pharmaceutical art.
  • the active ingredient will usually be mixed with a carrier, or diluted by a carrier and/or enclosed within a carrier which can, for example, be in the form of a capsule, sachet, paper or other container.
  • a carrier which can, for example, be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, excipient or medium for the active ingredient.
  • the composition can be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection solutions, suspensions, sterile packaged powders and as a topical patch.
  • a suitable mammal such as a rabbit, rat, or mouse. More preferably, the mammal is a human.
  • the compounds according to the invention may also be present as salts.
  • Pharmaceutically acceptable salts refers to an acid addition salt or a basic addition salt of a compound of the invention in which the resulting counter ion is understood in the art to be generally acceptable for pharmaceutical uses.
  • Pharmaceutically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
  • salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid
  • organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
  • Pharmaceutically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
  • ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine. (see, Berge et al. J. Pharm. ScL 1977, 66, 1-19).
  • p210Bcr-Abl-T315I is a theramutein of the p210Bcr-Abl protein (p210Bcr-AbI) that is resistant to inhibition by imatinib mesylate (Gleevec, STI-571).
  • the mutation at position 315 converts a threonine to an isoleucine residue and is one of several mutations that are observed among resistant or relapsed patients. This particular mutant, however, is the most resistant such theramutein yet identified.
  • a phenoresponse was determined for a Ba/F3 cell line engineered to overexpress the p2io Bcr"Abl"T3151 theramutein.
  • the phenoresponse was determined relative to non- transformed Ba/F3 cells and Ba/F3 cells that express the p2io Bcr"Abl wt prototheramutein.
  • the phenoresponse was the ability of the T315I mutants to grow to a higher cell saturation density under analogous culture conditions as compared to the control non-transformed Ba/F3 cell line, and to grow in the absence of interleukin 3 (IL-3), which is required for maintenance of the control non-transformed Ba/F3 cell line.
  • the phenoresponse was defined and characterized according to the teachings given above.
  • the detection system utilized was a high speed cell imaging and counting system in which 3 ⁇ l sample volumes of cells were sequentially injected through a 5 ⁇ l optical microcell, digitally imaged and electronically stored, scanned, and then counted, all under a microcomputer-based control system.
  • the system has the capacity to perform direct cell counts on samples from cultures as small as 500 ⁇ l and provides statistically significant total cell counts from culture samples containing as few as 12,500 cells. All of the figures displaying cell count and viability assays utilized this system for data acquisition and analysis.
  • the system is also capable of determining overall cell viability by distinguishing counted, imaged cells that have excluded trypan blue (counted as "viable” cells) from cells which have taken up the trypan blue dye (counted as "non- viable” cells). Injection of trypan blue into the cell sample occurs immediately prior to the sample being sequentially injected into the microcell for simultaneous cell counting and imaging.
  • the system may be integrated into the workflow of high-throughput screening devices to provide a sensitive and precise cell counting and cell viability assay system that is more reliable and less prone to confounding effects of metabolic viability-based cellular assays such as XTT or Alamar blue.
  • a total of approximately 11,760 compounds showed greater than 50% growth inhibition, which were thought to correspond to approximately 4500 distinct chemical classes. Retesting of these compounds with the same cell line yielded a database of compound responsiveness which was then sorted and rank ordered according to those compounds exhibiting the highest overall growth inhibition. From this rank ordered database, the highest scoring 130 compounds (based upon the greatest degree of growth inhibition observed at the lowest concentrations that compounds were tested) were then rescreened in a defined cell-based assay system using Ba/F3 T315I as test cells and wild type Ba/F3 as control cells according to the methods of the present invention.
  • the remaining five compounds were independently evaluated in additional cell-based assays using the aforementioned cell lines as well as in a cell-free purified protein kinase assay using human recombinantly produced 120 Kd kinase domain fragments isolated from both wild type P210 Bcr-Abl as well as P210 T315I mutant kinase domain.
  • FIG. 1 Representative examples of the cell-based assay results demonstrating selective inhibition of growth of the Ba/F3 T315I cell line relative to the wild type non- transformed Ba/F3 cells are shown in Figures 1 and 2.
  • the compounds inhibited growth and reduced the viability of cells expressing the T315I theramutein at concentrations under which the growth and viability of the wild type Ba/F3 non-transformed cells (not expressing either p210 Bcr - Abi - wt or p210 Bcf Abi - T3i5i ) were relatively unaffected, whereas cells expressing both the prototheramutein as well as the theramutein were substantially inhibited.
  • the T3151 expressing cells were inhibited to an even greater extent than the P210 prototheramutein expressing cells. (See, for example, Figure 3, right hand side, Compound 3 results against P210 and T315I cells.
  • the methods presented herein provide a fundamental advance in the form of a generalizable approach for creating or identifying modulators of any given theramutein.
  • the results demonstrate conclusively the power of the method to identify critically needed compounds to overcome a specific type of acquired drug resistance that is uniformly fatal in certain patient populations and is presently untreatable.
  • the techniques and methods described herein may, using obvious modifications, be straighforwardly generalized to any potential theramutein or other disease associated protein of clinical significance.
  • the phenoresponse-based assay system of the invention can be used to profile the biological activity of a given compound with respect to its ability to inhibit or activate multiple distinct protein targets to differing extents.
  • the skilled artisan may be interested in identifying or optimizing modulators of a given target protein where additional proteins are known that are distinct but highly related to the target POI.
  • Such protein families may consist of two or more members that share a high degree of homology at both the DNA and amino acid sequence levels, yet the family members may have distinct functions within the cell.
  • the skilled artisan may also choose to express two or three or even four distinct protein targets in a single Test Cell (or Test Cell line) and create a phenoresponse-based assay system useful for identifying compounds that are NOT selective among individual isozymes of a given protein family.
  • a phenoresponse-based assay system useful for identifying compounds that are NOT selective among individual isozymes of a given protein family.
  • lack of selectivity among individual family members may be preferable.
  • Ibuprofen for example, is an established, low-cost safe and effective nonsteroidal anti-inflammatory drug that does not significantly discriminate between the cyclooxygenase type 1 (COX-I) and COX-2 family members. Such lack of discrimination may in some instances be beneficial and may reduce the likelihood of certain unwanted side effects that may occur with an overly selective chemical agent.
  • this cross- reactive inhibition of the kit oncoprotein is serendipitous, because gastrointestinal stromal tumors (GIST), a type of tumor arising in the small intestine, are driven by kit activity and are thus responsive to imatinib treatment as well (Druker et al, NEJM, 2001, 344, 1031-1037).
  • GIST gastrointestinal stromal tumors
  • Such cross reactivity with other related proteins need not always be associated with toxicity of a drug. In some instances such cross-reactivities can be therapeutically effective.
  • Compounds tested on a given cell line that exhibited an IC 5O value that was ⁇ 1 O ⁇ M (less than 10 micromolar) were designated as Category "C” compounds.
  • Compounds tested on a given cell line that exhibited an IC 50 value that was > lO ⁇ M (greater than or equal to 10 micromolar) were designated as Category "D” compounds.

Abstract

L'invention concerne des agents qui sont des inhibiteurs ou des activateurs de formes variantes de protéines endogènes et de nouveaux procédés d'identification de telles variantes. Des inhibiteurs et des activateurs de variantes de protéine endogène, codés par des gènes qui ont muté, sont d'un intérêt particulier, lesquelles variantes apparaissent souvent ou sont au moins tout d'abord identifiées comme étant apparues à la suite d'une exposition à un agent chimique qui est connu pour être un inhibiteur ou un activateur de la protéine endogène non mutée correspondante.
PCT/US2008/002656 2007-02-27 2008-02-27 Modulateurs de théramutéine WO2008106202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90411507P 2007-02-27 2007-02-27
US60/904,115 2007-02-27

Publications (1)

Publication Number Publication Date
WO2008106202A1 true WO2008106202A1 (fr) 2008-09-04

Family

ID=39721555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/002656 WO2008106202A1 (fr) 2007-02-27 2008-02-27 Modulateurs de théramutéine

Country Status (1)

Country Link
WO (1) WO2008106202A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010098866A1 (fr) 2009-02-27 2010-09-02 Supergen, Inc. Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
US8796310B2 (en) 2011-05-04 2014-08-05 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
JP2018504449A (ja) * 2015-02-04 2018-02-15 ビヨンドバイオ インコーポレイテッド ヘテロ環化合物及びそれを含む薬剤学的組成物
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021035788A1 (fr) * 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 Dérivé de pyrazole et son utilisation
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041102A1 (fr) * 1996-05-01 1997-11-06 Ortho Pharmaceutical Corporation Derives carboxamide de pyrrolidine, piperidine et hexahydroazepine utilises dans le traitement de troubles thrombotiques
WO2005115992A1 (fr) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Modulateurs de theramuteine
WO2006047631A2 (fr) * 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Composes antimitotiques antiproliferatifs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041102A1 (fr) * 1996-05-01 1997-11-06 Ortho Pharmaceutical Corporation Derives carboxamide de pyrrolidine, piperidine et hexahydroazepine utilises dans le traitement de troubles thrombotiques
WO2005115992A1 (fr) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Modulateurs de theramuteine
WO2006047631A2 (fr) * 2004-10-25 2006-05-04 University Of Medicine And Dentistry Of New Jersey Composes antimitotiques antiproliferatifs

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
US8822518B2 (en) 2006-08-09 2014-09-02 Glaxosmithkline Llc Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
WO2010098866A1 (fr) 2009-02-27 2010-09-02 Supergen, Inc. Inhibiteurs cyclopentathiophène/cyclohexathiophène de l'adn méthyltransférase
US8796310B2 (en) 2011-05-04 2014-08-05 Merck Sharp & Dohme Corp. Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors
US9592232B2 (en) 2012-04-24 2017-03-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10076521B2 (en) 2012-04-24 2018-09-18 Vertex Pharamceuticals Incorporated DNA-PK inhibitors
US9925188B2 (en) 2012-04-24 2018-03-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors and uses thereof
US11021465B2 (en) 2012-04-24 2021-06-01 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10501439B2 (en) 2012-04-24 2019-12-10 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9376448B2 (en) 2012-04-24 2016-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11008305B2 (en) 2012-04-24 2021-05-18 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10442791B2 (en) 2012-04-24 2019-10-15 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9878993B2 (en) 2012-04-24 2018-01-30 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors for treatment of cancer
US10391095B2 (en) 2012-04-24 2019-08-27 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US9458129B2 (en) 2012-12-06 2016-10-04 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9107916B2 (en) 2012-12-06 2015-08-18 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9908865B2 (en) 2012-12-06 2018-03-06 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10173996B2 (en) 2012-12-06 2019-01-08 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9604961B2 (en) 2012-12-06 2017-03-28 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9714230B2 (en) 2012-12-06 2017-07-25 Celgene Quantical Research, Inc. Histone demethylase inhibitors
US10786512B2 (en) 2013-03-12 2020-09-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US10258627B2 (en) 2013-03-12 2019-04-16 Vertex Pharmaceutical Incorporated DNA-PK inhibitors
US11813267B2 (en) 2013-03-12 2023-11-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9987284B2 (en) 2013-03-12 2018-06-05 Vertex Pharmaceuticals Incorporated Substituted benzooxadiazole DNA-PK inhibitors
US10973830B2 (en) 2013-03-12 2021-04-13 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US10039761B2 (en) 2013-10-17 2018-08-07 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10716789B2 (en) 2013-10-17 2020-07-21 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
JP2018504449A (ja) * 2015-02-04 2018-02-15 ビヨンドバイオ インコーポレイテッド ヘテロ環化合物及びそれを含む薬剤学的組成物
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
WO2021035788A1 (fr) * 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 Dérivé de pyrazole et son utilisation

Similar Documents

Publication Publication Date Title
WO2008106202A1 (fr) Modulateurs de théramutéine
US11491164B2 (en) Theramutein modulators
WO2008091681A2 (fr) Modulateurs des théramutéines
US20100016298A1 (en) Theramutein modulators
US11714080B2 (en) Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
WO2007062213A2 (fr) Composes et procedes d’identification, de synthese, d’optimisation et de creation de profils de modulateurs de proteines
US20240125769A1 (en) Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
US20090275070A1 (en) Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators
AU2012203664B2 (en) Theramutein modulators
Class et al. Patent application title: Compounds and Method of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators Inventors: Gerard M. Housefly (Southfield, MI, US) Gerard M. Housefly (Southfield, MI, US) Hmi Medical Innovations, Llc. Assignees: HMI MEDICAL INNOVATIONS, LLC.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726229

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08726229

Country of ref document: EP

Kind code of ref document: A1